Ixekizumab COASTs through r-axSpA with sustained efficacy, safety
13 May 2020
byAudrey Abella
Two phase III trials reflect the sustained efficacy and safety of the bDMARD* ixekizumab in bDMARD-naïve (COAST-V) or TNFi**-experienced (COAST-W) adults with active radiographic axial spondyloarthritis (r-axSpA), also known as ankylosing spondylitis (AS).
Ixekizumab COASTs through r-axSpA with sustained efficacy, safety
13 May 2020